JP2019530719A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530719A5
JP2019530719A5 JP2019520040A JP2019520040A JP2019530719A5 JP 2019530719 A5 JP2019530719 A5 JP 2019530719A5 JP 2019520040 A JP2019520040 A JP 2019520040A JP 2019520040 A JP2019520040 A JP 2019520040A JP 2019530719 A5 JP2019530719 A5 JP 2019530719A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
wavelength
measured
temperature
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520040A
Other languages
English (en)
Japanese (ja)
Other versions
JP7068288B2 (ja
JP2019530719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056379 external-priority patent/WO2018069892A1/en
Publication of JP2019530719A publication Critical patent/JP2019530719A/ja
Publication of JP2019530719A5 publication Critical patent/JP2019530719A5/ja
Application granted granted Critical
Publication of JP7068288B2 publication Critical patent/JP7068288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520040A 2016-10-14 2017-10-13 4-(2-((1r,2r)-2-ヒドロキシシクロヘキシルアミノ)ベンゾチアゾール-6-イルオキシ)-n-メチルピコリンアミドの結晶形 Expired - Fee Related JP7068288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408358P 2016-10-14 2016-10-14
US62/408,358 2016-10-14
PCT/IB2017/056379 WO2018069892A1 (en) 2016-10-14 2017-10-13 Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide

Publications (3)

Publication Number Publication Date
JP2019530719A JP2019530719A (ja) 2019-10-24
JP2019530719A5 true JP2019530719A5 (enExample) 2020-11-19
JP7068288B2 JP7068288B2 (ja) 2022-05-16

Family

ID=60320932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520040A Expired - Fee Related JP7068288B2 (ja) 2016-10-14 2017-10-13 4-(2-((1r,2r)-2-ヒドロキシシクロヘキシルアミノ)ベンゾチアゾール-6-イルオキシ)-n-メチルピコリンアミドの結晶形

Country Status (14)

Country Link
US (1) US10934273B2 (enExample)
EP (1) EP3526217B1 (enExample)
JP (1) JP7068288B2 (enExample)
KR (1) KR20190064589A (enExample)
CN (1) CN109843880B (enExample)
AU (1) AU2017342239B2 (enExample)
BR (1) BR112019006914A2 (enExample)
CA (1) CA3039764A1 (enExample)
CL (1) CL2019001008A1 (enExample)
ES (1) ES2949414T3 (enExample)
IL (1) IL265893A (enExample)
MX (1) MX2019004345A (enExample)
RU (1) RU2019114208A (enExample)
WO (1) WO2018069892A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
CN103501785B (zh) * 2011-05-05 2016-10-26 诺瓦提斯公司 用于治疗脑肿瘤的csf-1r抑制剂
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies

Similar Documents

Publication Publication Date Title
JP2014525470A5 (enExample)
JP2015512942A5 (enExample)
JP6995043B2 (ja) リジン特異的デメチラーゼ-1の阻害剤を含む組成物
JP2016503010A5 (enExample)
NZ627750A (en) Carbamate compounds and of making and using same
JP4477097B2 (ja) 中枢神経系障害の治療のための(2s)−(4e)−n−メチル−5−[3−(5−イソプロポキシピリジン)イル]−4−ペンテン−2−アミンの多形形態
JP2012509321A5 (enExample)
JP2018516883A5 (enExample)
JP2022037122A (ja) 3-(イミダゾ[1,2-b]ピリダジン-3-イルエチニル)-4-メチル-N-{4-[(4-メチルピペラジン-1-イル)メチル]-3-(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形
JP6391436B2 (ja) 固形医薬組成物
JP5700740B1 (ja) 固形医薬組成物
JP2013516473A5 (enExample)
JP2018510179A (ja) イブルチニブとカルボン酸との共結晶
KR102593783B1 (ko) 결정성 화합물
JP2018531280A5 (enExample)
EP2181991A1 (en) Novel salts of sunitinib
JP7303821B2 (ja) ピリミジニルアミノ-ピラゾール化合物の多形体及び固体形態、ならびに製造方法
JP2012532125A5 (enExample)
JP2019530719A5 (enExample)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
JP2016537326A5 (enExample)
JP2018516946A5 (enExample)
JP2022535870A (ja) Cdk9阻害剤の結晶多形体及びその製造方法と用途
TW201638090A (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
JP2017507980A5 (enExample)